REVIEW ARTICLE

Unboxing the network among long non-coding RNAs and TGF-β signaling in cancer

Dorival Mendes Rodrigues-Junior and Aristidis Moustakas

Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden

ABSTRACT

Deeper analysis of molecular mechanisms arising in tumor cells is an unmet need to provide new diagnostic and therapeutic strategies to prevent and treat tumors. The transforming growth factor β (TGF-β) signaling has been steadily featured in tumor biology and linked to poor prognosis of cancer patients. One pro-tumorigenic mechanism induced by TGF-β is the epithelial-to-mesenchymal transition (EMT), which can initiate cancer dissemination, enrich the tumor stem cell population, and increase chemoresistance. TGF-β signals via SMAD proteins, ubiquitin ligases, and protein kinases and modulates the expression of protein-coding and non-coding RNA genes, including those encoding larger than 500 nt transcripts, defined as long non-coding RNAs (lncRNAs). Several reports have shown lncRNAs regulating malignant phenotypes by directly affecting epigenetic processes, transcription, and post-transcriptional regulation. Thus, this review aims to update and summarize the impact of TGF-β signaling on the expression of lncRNAs and the function of such lncRNAs as regulators of TGF-β signaling, and how these networks might impact specific hallmarks of cancer.

KEYWORDS
Cancer; epigenetics; non-coding RNA; signal transduction; transforming growth factor-β

 

 

Introduction

Signal transduction pathways serve as modulators of cellular physiology by acting on diverse systems that maintain cellular function, including the genome, whose expression is modulated, thus generating specific biological adaptations and responses that mediate new cellular behavior (1). For this reason, most signaling pathways become implicated in diseases, including cancer. The mammalian genomes contain a large number of genes, including genes that encode mRNAs and non-coding RNAs, such as, rRNA, tRNA, micro-RNA (miRNA), piwi RNA (piRNA), small nucleolar RNA (snRNA), long non-coding RNA (lncRNA), and more. We here aim at summarizing and critically evaluating evidence on the regulation of expression and function of lncRNAs by the transforming growth factor β (TGF-β) family of signaling pathways.

TGF-β signaling

A prominent developmental signaling pathway with strong implications in cancer is that of TGF-β (2), whose molecular constituents attract attention for the development of improved treatment of diverse tumor types (2). The dimeric ligand forms complexes with two similar plasma membrane receptors (type I, TGFβRI, and type II, TGFβRII), whose ligand-mediated protein complex results in the activation of the cytoplasmic protein kinase domain of TGFβRI (2). TGF-β binding to the two signaling receptors is facilitated by association with the heparan-sulfate proteoglycan co-receptor TGFβRIII or betaglycan or other co-receptors, which oligomerize with TGFβRII and TGFβRI (2). The TGFβRI protein kinase phosphorylates the C-terminal di-serine residues in SMAD family proteins, specifically SMAD2 and SMAD3, which then form complexes with SMAD4, thus stabilizing a transcriptional SMAD complex that associates with chromatin and modulates the expression of many different genes (3). The TGF-β receptors associate with other signaling proteins that lead to activation of protein and lipid kinases and of small GTPases (2). Such complementary signaling inputs can post-translationally modify the SMADs, their interacting transcription, or chromatin modulating co-factors, or alternatively, these inputs control the assembly and activity of cytoplasmic or membrane-associated factors that elicit the physiological response of cells to TGF-β (2). TGF-β signaling can also regulate splicing and maturation of specific mRNAs, processing of certain miRNAs, whereas miRNAs and other non-protein coding RNAs, such as lncRNAs, regulate different aspects of the signaling pathway (2, 4), as discussed in detail in this article (see Figure 1).

Figure 1. Network of lncRNAs and TGF-β signaling in cancer.
TGF-β binds to the type II and type I receptors (TβRs) on the cell surface, signaling via inter-receptor trans-phosphorylation. The type I receptor phosphorylates SMAD2/3, which promotes their oligomerization with SMAD4 (presented for simplicity as SMAD), and in parallel, TGF-β signaling induces RAS, MEK, ERK, and other protein kinase pathways (not shown), that, together with transcription factors (TFs), regulate the expression of lncRNAs (shown as multicolor single-stranded molecules in order to emphasize the diversity of the implicated lncRNA species). According to the respective cellular compartment, lncRNAs modulate TGF-β signaling at different steps. Nuclear lncRNAs act as (i) guide or decoy molecules for TF complexes to promote gene transcription (TSS, transcription start site) (ii) as DNA binding molecules inducing triple helix formations or (iii) facilitate protein translocation from one compartment to another. Cytoplasmic lncRNAs can regulate (iv) mRNA stability, (v) can act as scaffolds, stabilizing protein-RNA complexes, or (vi) can regulate mRNA translation and stability through competitive endogenous RNA (ceRNA) function against microRNAs (miRNAs). LncRNAs are also sorted as cargo in intraluminal vesicles of multivesicular bodies (MVBs), which release their lncRNA content into the extracellular milieu. Created with BioRender.com. TGF-β, transforming growth factor β; IncRNA, long non-coding RNAs.

The initial implication of a role of TGF-β1 in cancer biology was followed by the understanding that most other members of the TGF-β family, for example, the bone morphogenetic proteins (BMPs) and the activins, are also involved in cancer development, and each of these factors exhibits unique and tumor type-specific functions (5). Cancer cell biological research and in vivo mouse models of cancer coupled to a large number of studies in cancer patients have suggested with a high degree of confidence that TGF-β is a suppressor of pre-malignant hyperplasia in many solid and hematopoietic tumors, but is also involved in the progression of tumors, especially during the stages of dissemination of tumor cells via local or distant invasion and metastasis (2). The ability of TGF-β to arrest the cell cycle of epithelial, endothelial, hematopoietic, and other cell types contributes to the suppression of premalignant oncogenic tissue growth (2). TGF-β can also induce apoptosis in specific tissue types (e.g. liver and prostate) and thus antagonize tumorigenic development based on TGF-β’s homeostatic functions (2). In a different biological context of tumor development, TGF-β is a potent inducer of epithelial-mesenchymal transition (EMT), a cell differentiation change that promotes the dissemination of tumor cells away from the primary tumor, and a process that is not strictly associated with epithelial tumor cells (in carcinomas), but is also relevant for a variety of other tumors, including brain and hematopoietic tumors (6). TGF-β also acts as pro-stemness factor that helps the survival and maintenance of cancer stem cells (7). Possibly, the most powerful action of TGF-β in cancer is the suppression of immune cell proliferation and differentiation, making TGF-β a very potent agent that helps the long-term survival of tumors and the inactivation of the immune response against the tumor (2).

Long non-coding RNAs

All genomes contain lncRNA genes, including those whose function was elucidated since the early days of molecular biology (rRNAs and tRNAs) (8). Until the year of 2021, about 20,000 different lncRNAs were described (9). Their majority map at distinct chromosomal regions away from protein-coding genes, yet some lncRNAs are transcribed from the antisense strand of a protein-coding cistron, which may or may not overlap with the mRNA, and other are completely embedded into an intron or alternatively share a common transcriptional promoter with a protein-coding gene (8).

LncRNA genes generate mature RNAs of more than 500 nt length and are normally produced by the same transcriptional, maturation, and splicing mechanisms catalyzed by RNA polymerase II and capping and polyadenylating enzymes as those of mRNAs (8). A major difference and aspect of debate that has been difficult to experimentally resolve is the extent to which open reading frames recognized in the sequence of mature lncRNAs are functionally translated into polypeptides or not. In general, regulatory features of the lncRNA secondary structure are frequently considered as determinants of translatability of lncRNAs (8), whereas studies of direct ribosomal association with lncRNAs and their translation into polypeptides are most frequently bypassed. Accordingly, some previously defined lncRNAs were shown to generate short polypeptides with physiological function, such as the homeobox B cluster antisense RNA 3 (HOXB-AS3), whose 53 amino acid-long polypeptide regulates alternative splicing of the pyruvate kinase M in colorectal cancer (CRC) cells (10). Growing evidence though suggests a more universal function of lncRNAs as components of large ribonucleoprotein assemblies that regulate cell biological processes in the nucleus, on chromatin or in the cytoplasm and even near the plasma membrane (8).

In the context of cancer, lncRNA expression can be misregulated, thus facilitating specific steps in cancer development, partially due to the demonstrated function of lncRNAs in normal stem cell viability and the control of cell differentiation (8). LncRNAs not only function by interacting with proteins but also assemble triple-helices with DNA strands on chromatin and base-pair with other RNAs, including miRNAs, acting as competing endogenous RNAs (ceRNAs) that sequester miRNAs into specific cellular subcompartments (8). All of these mechanisms have been demonstrated to be functionally important in cancer cell biology (see Figure 1). It is therefore interesting and important to research and uncover unknown mechanisms and functional links between lncRNAs and signaling pathways such as TGF-β, which is implicated in all aspects of cancer development. Since the majority of lncRNA genes remain functionally unexplored, this field of research promises exciting future discoveries.

Breast cancer

Breast cancer (BRCA) was estimated by the World Health Organization (WHO) as one of the most frequent tumors worldwide, reporting 2.3 million new cases in 2020 and 685,000 BRCA-related deaths (11). lncRNAs contribute to our understanding of BRCA biology, and as potential new biomarkers and therapeutic targets to defeat this disease (12). In line with this, the expression of lncRNA-activated by transforming growth factor beta (lncRNA-ATB), one of the first lncRNAs described to be induced upon TGF-β signaling activation (13), has been correlated with the worst prognosis of BRCA patients and trastuzumab resistance by competing with miRNAs (14). Additionally, circulating lncRNA-ATB can be used as a non-invasive diagnostic marker in serum for early stages of BRCA (15). Nevertheless, how TGF-β signaling induces lncRNA-ATB expression has been poorly explored. A distinct lncRNA with prognostic potential in several tumors, including BRCA, is the Smad/Myc coactivator or LOC284454 (Smyca) (16). Smyca expression can be induced by TGF-β signaling via SMAD, and in triple negative BRCA (TNBC) cells, Smyca promoted TGF-β/SMAD signaling by binding to the MH1 domains of SMAD3 and SMAD4, but not SMAD2, thus increasing the stability of the SMAD3/4 complex, leading to the expression of TGF-β responsive genes, responsible for EMT, cell motility, and drug resistance. Moreover, Smyca bound to c-Myc independently of SMAD3/4. Interestingly, the balance promoted by c-Myc and SMAD3/4 in competing for this lncRNA was shown to modulate glycolysis (16). Of note, after activation of TGF-β signaling, the SMAD complex can be formed either in the cytosol or in the nucleus (2), and Smyca was characterized as a nuclear lncRNA. Since binding of Smyca with SMAD3 or SMAD4 was described without activating TGF-β signaling, probably Smyca can bind to non-active SMADs shuttling in the nucleus. Notwithstanding, this study described novel mechanisms about a lncRNA stabilizing the TGF-β signaling protein complex in BRCA.

Additional lncRNAs reported as potentially poor prognostic markers for TNBC patients were the tumor suppressor candidate 7 (TUSC7) and ADAMTS9 antisense RNA 2 (ADAMTS9-AS2) (17, 18). TUSC7 can bind to miR-1224-3p, and its overexpression decreased cell motility and promoted the sensitivity of MDA-MB-468 cells to cytotoxic drugs, while TUSC7 knockdown in MDA-MB-231 cells enhanced TGFBR2 levels, suggesting a negative role of TUSC7 on TGF-β signaling (18). Furthermore, ADAMTS9-AS2 can interact with and modulate the expression of the ribosomal protein L22 (RPL22) (17). These data were further correlated with the translational downregulation of TGFBRI and SMAD2, thereby modulating TGF-β signaling negatively. RPL22 can bind to intronic sequences in the SMAD2 pre-mRNA, inducing exon 9 skipping, which reduced SMAD2 protein levels (19). Additionally, ADAMTS9-AS2 overexpression suppressed proliferation and invasion of TNBC cells in culture and in vivo, which is consistent with TGF-β signaling controlling TNBC progression (17). Nevertheless, mechanistically, how ADAMTS9-AS2 interacting with RPL22 could negatively modulate TGFBR1 expression, and how TUSC7 and ADAMTS9-AS2 expressions could be regulated were not explored. Conversely to TUSC7 and ADAMTS9-AS2, the loss of function assays of thymopoietin antisense transcript 1 (TMPO-AS1) in MDA-MB-231 cells revealed a reduction of gene signatures related to TGF-β signaling, as shown by TGFBR1 and TGFBR2 expression, in comparison to the cells expressing TMPO-AS1 (20). SiRNA-based treatment against TMPO-AS1 impaired proliferation and migration of TNBC using in culture and in vivo models (20). Furthermore, the activation of TGF-β signaling in BRCA cells induced the expression of the lncRNA urothelial cancer associated 1 (UCA1) (21), and its expression was further associated with doxorubicin resistance. However, mechanistically, how can TMPO-AS1 modulate TGFBR1 and TGFBR2 expressions, and how can UCA1 promote doxorubicin resistance apart from inducing TGF-β signaling was not elucidated.

A novel lncRNA positively regulating TGF-β signaling is the lncRNA enforcing TGF-β signaling 1 (LETS1) (22). LETS1 is a nuclear lncRNA induced by TGF-β–SMAD signaling that induced EMT and migration in breast and lung cancer cells. RNA immunoprecipitation (RIP) and RNA pull-down assays revealed a protein-RNA complex among LETS1 and the nuclear factor of activated T cells (NFAT5), thus LETS1 enhancing NFAT5 binding to the orphan nuclear receptor 4A1 (NR4A1) promoter. It is important to mention that NR4A1 formed protein complexes with AXIN2 and RNF12 or ARKADIA to facilitate SMAD7 polyubiquitination and its subsequent degradation (23). Consequently, this process initiated by LETS1 could inhibit TGFβRI polyubiquitination via SMAD7, thus establishing a positive feedback loop for TGF-β–SMAD signaling.

Of importance, since lncRNAs also regulate biological responses through encoding micropeptides, the long intergenic non-protein coding RNA 665 (LINC00665) could be translated to the CIP2A binding peptide (CIP2A-BP, a 52-amino acid peptide), whose translation was downregulated after TGF-β signaling activation in BRCA cells (24). Mechanistically, upon TGF-β stimulation, SMAD4 directly induced 4E-BP1 expression, which interacted with the translation initiation factor eIF4E and decreased CIP2A-BP synthesis. Furthermore, immunoprecipitation assays revealed that the cancerous inhibitor of protein phosphatase 2A (CIP2A) B56γ subunit directly bound to CIP2A-BP (24). Thus, CIP2A-BP can release PP2A activity through competitive binding, which inhibits the PI3K/AKT/NF-κB pathway, followed by the reduction of MMP-2, MMP-9, and SNAI1 expression. Additionally, low CIP2A-BP, but not LINC00665, expression in TNBC patients correlated with metastasis and poor overall survival. Hence, TGF-β signaling can lead to TNBC metastasis partially due to the downregulation of CIP2A-BP translation (24).

Ovarian cancer

Ovarian cancer (OC) is a major cause of lethality related to gynecological tumors with 295,000 new cases and 185,000 deaths annually worldwide (25). Thus, non-coding RNAs emerge not only as novel promising biomarkers for OC prognosis but also as therapeutic targets to prevent OC metastasis and inevitably chemoresistance, which is coupled to tumor recurrence and poor outcome of OC patients (26). Based on available human cancer datasets, higher cancer susceptibility candidate 15 (CASC15) expression correlated with the poor prognosis of OC patients (27). Mechanistically, CASC15 acted as ceRNA targeting miR-23b-3p and miR-24-3p and their sequestration cooperatively upregulated the levels of SMAD3, triggering the EMT program, which led to cell migration and invasion of OC cells in culture and in vivo (27). Another lncRNA expressed at advanced stages of OC patients, which correlated with poor overall survival, progression-free survival, and post-progression survival according to human cancer datasets, was the prostate cancer-associated transcript 6 (PCAT6) (28). Functionally, PCAT6 increased the proliferation and motility of OC cells in culture and by targeting miR-143-3p, as previously reported in pancreatic ductal adenocarcinoma (29). This lncRNA induced the expression of TGF-β-activated kinase 1 (TAK1/MAP3K7), which is a serine/threonine kinase of the MAP3K family and critical regulator of TGF-β signaling (28). Additionally, in the context of OC, PVT1 can possibly regulate the TGF-β pathway by sponging miR-148a-3p, which upregulates AGO1 expression and increases p-SMAD2 and p-ERK1/2 levels (30). Although PVT1 expression was significantly higher in OC tissues in comparison to non-tumor ovaries, its expression was also correlated with advanced FIGO (International Federation of Gynecology and Obstetrics) stage III-IV, comprising tumor size and lymph-node metastasis, besides poor survival of OC patients. LINC02323 was also relevant to TGF-β pathway regulation in OC cells by acting as ceRNA for miR-1343-3p (31), as also reported in lung adenocarcinoma cells (32), which eventually increased TGFBR1 levels and, therefore, enhanced TGF-β signaling. Furthermore, LINC02323 exhibited significantly higher serum levels in OC patients in comparison to normal volunteers, and its function could contribute to OC metastasis. However, how PCAT6, PVT1, and LINC02323 expressions were modulated in OC cells was not discussed and remains an open question.

It is established that extracellular vesicles (EVs) carry molecules associated with the TGF-β pathway, including non-coding RNAs (33). In line with this, Yuan et al. claimed that lncRNA ATB present in OC-derived EVs could modulate tumorigenesis via sponging the miR-204-3p, which downregulates TGFBR2 expression (34). However, this study had limitations since it did not clarify whether this lncRNA was naturally associated with OC-derived EVs or was found enriched in vesicles due to the isolation method (e.g. force of centrifugation).

Endometrial cancer

Endometrial cancer (EC) is a fatal malignancy among women globally, and the emerging role of lncRNAs and their dysregulation in EC has been explored in recent studies (35). In this context, overexpression of MIR210HG induced Wnt/β-catenin and TGF-β/SMAD3 signaling pathway genes by acting as ceRNA, sponging miR-337-3p and miR-137 to regulate HMGA2 expression, which promoted the expression of EMT-TFs (SNAI1 and SNAI2) and increased EC cell motility (36). Nevertheless, how MIR210HG expression was modulated in EC cells was not discussed.

Head and neck cancer

Head and neck cancer is the seventh most common tumor worldwide, affecting 880,000 new patients and causing 300,000 deaths every year (25). These tumors arise from the mucosa of distinct head and neck topologies, including the oral cavity, pharynx, and larynx, with squamous cell carcinomas (HNSCC) being the most frequent subtype, and due to its higher recurrence, only 30–50% of patients with locally advanced disease survive more than 5 years (37). Dysregulation of lncRNA expression affecting HNSCC tumorigenesis has been reported, providing also new mechanisms toward therapeutic strategies for this highly metastatic tumor (38). Accordingly, LINC01116 can be highly expressed in HNSCC tissues, and its expression correlated with shorter overall survival and relapse-free survival, based on patient data in the GEO database (39). Additionally, LINC01116 silencing inhibited invasion of HNSCC cells by blocking EMT, which was in line with a reduction in SNAI1 and SNAI2 expressions (39). Another lncRNA that could promote TGF-β signaling, inducing motility of HNSCC cells was the MIR4435-2HG (40). MIR4435-2HG overexpression led to upregulation of TGF-β1 expression, although exogenous TGF-β1 stimulation had no impact on MIR4435-2HG expression. Notwithstanding, mechanistically, how LINC01116 and MIR4435-2HG expressions are regulated, apart from how LINC01116 could affect the signature of genes related to TGF-β signaling and how MIR4435-2HG promoted TGF-β1 upregulation was not investigated in depth.

In tongue SCC (TSCC) tumors, the most prevalent malignancy in the oral cavity, cancer susceptibility 18 (CASC18), acted as a ceRNA to sponge miR-20a-3p, enhancing TGF-β2 expression and secretion, which consequently contributed to EMT (41). Higher CASC18 expression was associated with the status of occult lymph node metastasis in TSCC cohorts, but it was not discussed how its expression could be modulated. Moreover, the lncRNA SBF2 antisense RNA 1 (SBF2-AS1) was proposed to sponge miR-302b-3p, upregulating TGFBR2 expression in laryngeal SCC cells (42). Of note, considering the key role of TGF-β signaling in promoting EMT in laryngeal SCC cells (43), and since SBF2-AS1 could induce TGFBR2 expression, it would be expected that this lncRNA could enhance EMT. However, upon knockdown of SBF2-AS1, laryngeal SCC cells became more invasive, with higher expression of EMT markers (e.g. vimentin and N-cadherin), which, in turn, is contradictory to the lower levels of TGFBR2. Hence, although low SBF2-AS1 expression was correlated to lymph node metastasis and to advanced clinical stage, the mechanism of SBF2-AS1 regulating EMT in HNSCC may not involve TGF-β signaling. In a screen for lncRNAs regulated by TGF-β signaling during EMT, the lnc-PNRC2-1 was the most significantly upregulated lncRNA after TGF-β stimulation for 24 h in nasopharyngeal carcinoma cells (44). Knockdown of lnc-PNRC2-1 reduced the expression of EMT markers, although the mechanisms of lnc-PNRC2-1-modulating EMT and TGF-β signaling remain to be clarified. On the other hand, EPB41L4A-AS2 is a lncRNA whose expression is attenuated by TGF-β signaling in nasopharyngeal carcinoma cells (45). Overexpression of EPB41L4A-AS2 reduced the motility of HNSCC cells in culture and in vivo, and mechanistically, EPB41L4A-AS2 bound to YBX1 in the nucleus, to reduce the stability of SNAI1 mRNA, decreasing EMT progression, while in the cytoplasm, EPB41L4A-AS2 sponged miR-107, promoting LATS2 expression. Although the mechanism by which EPB41L4A-AS2 was repressed by TGF-β signaling was not revealed, these findings contributed to novel understanding about lncRNAs modulated by the TGF-β pathway and regulating EMT and metastasis in HNSCC cells.

Lung cancer

Similar to the previous tumor types, lung cancer remains a major health threat worldwide (11), and cases of lung cancer cell regulation by lncRNAs that link to the biology of TGF-β have been reported. The majority of such reports have analyzed non-small cell lung cancer (NSCLC) cells or patients. These include oncogenic lncRNAs that, via different molecular mechanisms, activate or promote TGF-β signaling. MIR100HG can be transcriptionally induced by TGF-β signaling to generate both a lncRNA and processed miRNAs (46). While the function of the encoded miRNAs remains unclear, the full-length MIR100HG transcript associated with the RNA binding protein HuR, which simultaneously bound to the TGFB1 mRNA. This caused its stabilization and, thus, promoted secretion of pro-oncogenic TGF-β1 protein in lung cancer cells (46). The TF FOXP3, which is best known for inducing differentiation of regulatory T cells, can also be misexpressed in NSCLC cells, thus inducing the expression of LINC01232 that associates directly with the IGF2BP2 protein; IGF2BP2 is an RNA-binding protein that associated with and stabilized the TGFBR1 mRNA, thus causing an indirect enhancement of pro-oncogenic TGF-β signaling in the lung cancer cells (47). LINC00511, which is selectively overexpressed in NSCLC patients, can function as a ceRNA for miR-98-5p, another negative regulator of TGFBR1 mRNA expression, thus making LINC00511 an activator of pro-oncogenic TGF-β signaling in NSCLC (48). The small nucleolar RNA host gene 3 (SNHG3) can be highly expressed in NSCLC possibly due to the transcriptional activation of its gene by E2F1 and belongs to the general class of ceRNAs that sponge miRNAs (49). Since chemical inhibitors against TGFβRI blocked the proliferative and migratory actions of overexpressed SNHG3, this lncRNA was postulated to activate TGF-β signaling (49). However, chemical inhibition of JAK2 signaling also blocked the proliferative and migratory actions of overexpressed SNHG3, implicating also interleukin-6 signaling. In this case, the ceRNA function of SNHG3 has not been established, and identifying miRNAs that inhibit TGF-β or interleukin-6 signaling maybe a relevant mechanism to examine in the future. A very similar mechanism involves MIR4435-2HG that is highly expressed in NSCLC, which was bioinformatically predicted to sponge distinct miRNAs that can target the TGFB1 mRNA, thus indirectly enhancing TGF-β signaling that was required for lung cancer cell proliferation and migration (50).

LncRNAs can also regulate TGF-β signaling at the level of SMAD protein function. The non-coding RNA activated by DNA damage (NORAD) associated with importin-β1, which also bound to SMAD3 and mediated its nuclear translocation in lung adenocarcinoma cells (51). Thus, a subset of genes regulated by TGF-β received an enhanced signal, and these included genes of the EMT program that facilitate lung cancer cell migration (51). Induction of expression of AC026904.1 by TGF-β signaling correlated with high expression of this lncRNA in metastatic lung cancer and AC026904.1 further induced transcription of SNAI2 via a yet uncharacterized molecular mechanism (52). AC026904.1 possibly provides a molecular link between lung cancer metastasis and TGF-β/SNAI2 expression during EMT. Also implicated in the EMT process is the TGF-β-inducible LINC00273, whose ceRNA function sponged a well-established negative regulator of EMT, the miR-200a-3p, and directly limited the expression of ZEB1, a mechanism that explains a strong pro-metastatic action of LINC00273 (53). At the end stages of metastasis, circulating lung cancer cells can colonize the brain, and before this, they must pass through the blood–brain barrier of capillaries. Such circulating lung cancer cells responded to TGF-β signaling by inducing secretion of EVs that carry the lncRNA lnc-MMP2-2, which acted as a ceRNA for miR-1207-5p (54). One of the molecular targets of miR-1207-5p can be the mRNA for the EPB41L5 adaptor protein that participates not only in the Crumbs complex that organizes epithelial tight junctions but also in invadopodia associated with integrins. The proposed model suggests that metastatic cells, by secreting EVs in response to TGF-β, transmit lnc-MMP2-2 to endothelial cells that eventually stabilize EPB41L5, causing a more permeable blood–brain barrier and facilitating the metastatic colonization (54).

While all previous lung cancer examples contribute to activation or enhancement of TGF-β signaling, lncRNAs can also limit or inhibit this signaling pathway. Accordingly, SMAD3-associated long non-coding RNA (SMASR) can be transcriptionally repressed by SMAD signaling (55). SMASR interacted directly with SMAD3, and their complex associated with the chromatin of the TGFBR1 gene causing its repression, thus limiting TGF-β signaling and lung cancer EMT (55). An independent lncRNA-mediated mechanism operated at the TGFβRI protein stability level. LITATS1 can be under-expressed in NSCLC tissue relative to normal lung epithelia and molecularly associated with TGFβRI and its E3 ubiquitin ligase SMURF2 (56). This RNA-mediated protein complex caused degradation of TGFβRI, thus limited TGF-β signaling, whereas tumor cells in which LITATS1 was downregulated presented enhanced TGF-β signaling and EMT (56). Additional lncRNAs acting at the chromatin level include the TGFB2 antisense RNA 1 (TGFB2-AS1), whose expression can be induced by TGF-β in lung adenocarcinoma and other cell types. This lncRNA could interact with the polycomb repressor complex 2 adaptor protein embryonic ectoderm development (EED), thus blocking full responsiveness of genes to TGF-β signaling (57). A similar mechanism, but via interaction between TGFB2-AS1 and the SWI/SNF chromatin remodeling protein SMARCA4, has been shown to mediate partial blocking of gene expression to TGF-β signaling, but in the context of BRCA cells (58). Whether lncRNA partners with distinct but functionally equivalent proteins regulate TGF-β signaling is an interesting concept that needs to be explored deeper.

Pancreatic adenocarcinoma

The 5-year survival rate for pancreatic adenocarcinoma (PDAC) remains below 8%, corresponding to the seventh leading cause of cancer-related death worldwide. LncRNAs, such as HOTAIR, HOTTIP, MALAT1, H19, PVT1, GAS5, MEG3, and ENST00000480739, have been linked to modulation of growth and invasion of PDAC cells (59). Additionally, MIR31HG (or long non-coding HIF-1α co-activating RNA – lncHIF-CAR) can be upregulated by TGF-β signaling in PDAC cells (60). The levels of MIR31HG were further correlated with the EMT gene signature in PDAC patient datasets, and its higher expression was associated with worse disease-free survival in patients. Moreover, MIR31HG silencing downregulated TGF-β-induced EMT, but the questions about how TGF-β modulated MIR31HG expression and how mechanistically MIR31HG promoted the TGF-β-induced EMT were not addressed (60). Another lncRNA that increases cell proliferation and invasion of PDAC cells and might play a role in TGF-β signaling was the X-inactive specific transcript (XIST) (61). This lncRNA sponged miR-141-3p, a negative regulator of TGFB2 transcripts. The highly upregulated in liver cancer (HULC) is another lncRNA, whose expression can be induced by TGF-β in PDAC cells and in PDAC-derived EVs (62). Since HULC silencing via siRNA or microRNA-133b decreased PDAC cell invasion by inhibiting the EMT, the authors proposed that HULC could be transferred to neighboring cells by PDAC-EVs, in order to promote EMT, although the mechanism of how HULC can modulate EMT in PDAC cells remains not fully understood. Furthermore, the enrichment of HULC-associated EVs present in the serum of PDAC patients showed good predictive power for discriminating PDAC patients, suggesting a novel tool for the early diagnosis of human PDAC (62). Nonetheless, the long intergenic non-coding RNA 261 (LINC00261) was downregulated upon TGF-β stimulation in PDAC cells (63). The TF forkhead box protein A2 (FOXA2) directly bound to the LINC00261 promoter, inducing the expression of this nuclear lncRNA. It has been shown by others that TGF-β signaling transcriptionally represses FOXA2 expression (64), which suggested that TGF-β could decrease LINC00261 expression by downregulating FOXA2 levels, although whether this could happen through a SMAD-dependent or -independent mechanism remains to be characterized. Moreover, a regulatory network between FOXA2 and LINC00261 regulated E-cadherin expression, which is an important epithelial cell adhesion protein (63). In view of this, the authors proposed that the repression of FOXA2 and LINC00261 expression by TGF-β facilitated EMT by triggering the loss of E-cadherin-dependent adherence junctions and, consequently, enhanced invasiveness of PDAC cells.

Hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the major subtype of liver cancer and one of the most frequent and lethal malignancies worldwide. To better understand HCC tumorigenesis, several studies reported lncRNAs modulating malignant phenotypes in HCC cells (e.g. evading apoptosis or enhancing cell proliferation and invasion) through their functional activity associated with DNA, RNA, or proteins (65). The mechanisms of lncRNAs and TGF-β in HCC initiation and development have been previously reviewed (66). We therefore discuss mainly more recent reports. The lncRNA nicotinamide nucleotide transhydrogenase-antisense RNA1 (NNT-AS1) could impair CD4⁺ T cell infiltration via the activation of TGF-β signaling in HCC cells (67). The authors proposed that NNT-AS1 contributed positively to TGFB1, TGFBR1, and SMAD5 expressions in HCC cells, although the mechanism of such regulation was not described. Additionally, NNT-AS1 levels were significantly increased in HCC tissues in comparison to normal tissues, and the elevated NNT-AS1 levels were correlated with poor patient overall survival. Similarly, the expression of maternally expressed gene 8 (MEG8) was increased in HCC and correlated with the poor prognosis of HCC patients (68). Interestingly, the authors suggested that MEG8 enhanced 14-3-3ζ expression by acting as a ceRNA of miR-367-3p. Thus, based on other studies (69), 14-3-3ζ might suppress TGFβR1 degradation, thereby enhancing TGF-β signaling, which provided HCC cells overexpressing MEG8 a higher ability to proliferate, migrate, and invade. In the context of ceRNA function in HCC, SET-binding factor 2 antisense RNA1 (SBF2-AS1) bound to the miR-361-5p, which, in turn, negatively regulated TGFB1 expression, affecting HCC proliferation and migration (70). Whether the expression of NNT-AS1 and SBF2-AS1 could be modulated by TGF-β signaling remains unknown.

As noted in PDAC (63), Linc00261 was also downregulated by TGF-β1 in HCC cells, and its downregulation facilitated EMT and stemness by increasing SNAI2 and ZEB1, OCT4, and SOX2 expressions (71). Mechanistically, the authors claimed that Linc00261 induced SMAD3 ubiquitin-proteasome-mediated degradation, which consequently led to decreased amounts of phosphorylated SMAD3. However, the authors did not demonstrate whether Linc00261 modulated SMAD3 directly or indirectly, e.g. via binding to SMAD3 or not. In addition, possible effects of Linc00261 on SMAD2 or non-SMAD signaling were not investigated. Nevertheless, the in-culture and in vivo evidence that Linc00261 overexpression could inhibit TGF-β signaling in HCC cells is strong (71).

Colorectal cancer

CRC is the second leading cause of cancer death in men and women combined worldwide (11), and lncRNAs are considered important players for the molecular mechanisms driving the initiation, progression, and metastasis of CRC (72). Similar to BRCA (14) and HCC (13) patients, high lncRNA‑ATB expression was associated with poor overall survival of CRC patients, besides advanced TNM stage, comprising tumor extent (T), spread to lymph node (N), or metastasis (M) to distant sites (73, 74). Notably, different studies observed that lncRNA‑ATB promoted CRC cell growth and motility through its role as a ceRNA to miR‑141‑3p (74) or to miR-200c, which, in turn, targeted CDK2 expression (73). These findings are in line with the demonstration that lncRNA-ATB knockdown also inhibited CRC growth, besides colony and sphere formation (75). Furthermore, lncRNA-ATB could inhibit β‑catenin expression, an oncogenic factor in CRC (75). Another lncRNA highly expressed in CRC patients and induced by TGF-β is the taurine upregulated gene 1 (TUG1), whose knockdown decreased EMT, followed by the reduction of CRC cell motility in culture and inhibition of CRC lung metastasis in vivo (76). Mechanistically, TUG1 appeared to act downstream of TGF-β signaling by modulating the expression of TWIST1, as the silencing of TUG1 decreased the levels of TWIST1 induced by TGF-β in CRC cells. Nevertheless, how TGF-β signaling induced TUG1 expression, via SMADs or not, remains open for debate. An additional ceRNA affecting firmly TGF-β signaling is LOC646329-variant D, whose overexpression suppressed CRC progression through sponging miR-29b-1, which is harbored at the third intron of LOC646329, followed by the upregulation of SMAD3 and p21 levels, while cyclinD1 was downregulated, shifting a high percent of the CRC cell population to the G1 phase (77). Furthermore, the expression of the lncRNA CTBP1 divergent transcript (CTBP1-DT or CTBP1-AS2) was associated with worse overall survival of CRC patients and positively correlated with TGFB1, SMAD2, and SMAD3 in both colon and rectal adenocarcinoma patients (78). CTBP1-AS2 enhanced TGF-β signaling, in addition to affecting CRC cell proliferation and invasion, by sponging and inhibiting miR-93-5p function, which potentially targets TGFB1 mRNA. However, whether the other LOC646329 variants could impact miR-29b-1 levels and how the expression of CTBP1-AS2 and LOC646329 is modulated by TGF-β remains poorly explored.

LINC00941, whose expression is induced by TGF-β, promoted EMT in CRC cells by directly binding the MH2 domain of SMAD4, as shown by RIP and RNA pulldown assays (79). LINC00941 competed with the β-transducin repeats-containing protein (β-TrCP) E3 ubiquitin ligase to bind SMAD4, and this competition prevented SMAD4 degradation, thus activating TGF-β signaling, which induced the expression of cell invasion and metastasis genes (e.g. vimentin, fibronectin, and TWIST1), while decreased the levels of the main invasion suppressors E-cadherin and ZO-1 in CRC cells (79). Moreover, higher expression of LINC00941 was associated with poor prognosis of CRC patients (79). Yet, in the context of CRC, the expression of lncRNA small nucleolar RNA host gene 10 (SNHG10) was upregulated in tumor tissues and associated with poor prognosis of CRC patients (80). Furthermore, since the activation of TGF-β signaling might affect the sorting of molecular cargo from tumor-derived EVs (33), CRC cells (SW480) were kept in the presence of TGF-β for 72 h, and upon EV isolation followed by RNA sequencing, high enrichment of SNHG10 was found relative to EVs derived from non-stimulated cells (80). Functionally, EV-associated SNHG10 promoted CRC growth and suppressed NK cells in vivo by upregulating inhibin-βC (INHBC) expression in NK recipient cells, but how mechanistically TGF-β signaling affected the sorting of SNHG10 to CRC-derived EVs was not addressed.

Bladder cancer

The repertoire of lncRNAs correlated with the occurrence and development of bladder cancer (BC), a urological malignancy associated with high mortality and morbidity, includes UCA1, HOTAIR, MEG3, H19, GAS5, and MALAT1 (81). PLAC2 acted as a tumor suppressor lncRNA in BC since its expression was downregulated in tumors when compared to non-cancer tissues. By unknown mechanism(s), PLAC2 induced miR-663 expression, which targets TGFB1, decreasing invasion of BC cells (82). Moreover, MIR497HG and its two harbored miRNAs, miR-497 and miR-195, were also downregulated in BC cells (83). Interestingly, the function of MIR497HG was related to its harbored miRNAs, which coordinately suppressed multiple key components in the Hippo/YAP and TGF-β pathways, particularly attenuating the interaction among YAP and SMAD3, thus affected cell growth and invasion in culture. In addition, the E2F4 TF was critical to repress MIR497HG transcription in BC cells. On the other hand, Linc02470 was identified in the lnCAR database as one of the most upregulated lncRNAs expressed during BC initiation and progression (84). In the context of TGF-β signaling, Linc02470 directly targeted the miR-143-3p, promoting SMAD3 expression, which consequently induced SNAI1, SNAI2, ZEB2, vimentin, and N-cadherin expression. Hence, this lncRNA plays a role in promoting the EMT and increasing motility of BC cells. Furthermore, cancer susceptibility candidate 9 (CASC9) was also significantly upregulated in BC cells when compared to normal bladder tissues (85). Functionally, CASC9 acted as a ceRNA for miR‑758‑3p, a miRNA which repressed TGFB2 expression. Thus, by enhancing TGF‑β2 levels in BC cells, CASC9 promoted EMT and invasion (85). Notwithstanding, the mechanisms representing how Linc02470 and CASC9 expressions were induced or the repression of PLAC2 in BC cells occurred were not explored, necessitating further studies. LINC01451 can be highly expressed in BC in comparison to normal tissues, and its high expression correlated with poor prognosis of patients (86). Upon the pull-down assay of biotinylated LINC01451, direct interaction of LINC01451 with LIN28A and LIN28B (both being RNA binding proteins) was found, which promoted BC cell proliferation, invasion, and metastasis. Since TGFBRI and TGFBRII expressions were decreased in the absence of LINC0145 in BC cells, a reduction of EMT induced by TGF-β signaling was noted, which subsequently abrogated BC progression (86). Nevertheless, how LINC01451 relying on LIN28A and LIN28B modulated the TGF-β receptors to promote EMT remains unclear.

Prostate cancer

Prostate cancer, a serious tumor type in men, makes no exception to the importance of lncRNA-mediated functions that relate to different hallmarks of cancer (11). Although TGF-β signaling does not seem to regulate expression of NCK1-AS1, this lncRNA was highly expressed in prostate carcinomas and underexpressed in normal or even benign hyperplastic prostate tissue and seems to activate TGFB1 mRNA and TGF-β signaling via as yet unknown molecular mechanism (87). In contrast, the MIR100HG gene that was described in the lung cancer section was transcriptionally induced by TGF-β and formed a feed-forward signaling loop by facilitating TGFB1 mRNA stabilization and growth factor secretion by prostate cancer cells (46). Similarly, prostate cancer-associated transcript-7 (PCAT7) expression was induced by TGF-β signaling via a SMAD3 and SP1 TF-dependent mechanism (88). This mechanism seems to mark primary prostate carcinomas with a strong potential for metastasis to the bone. Furthermore, one possible function of PCAT7 is to serve as ceRNA for miR-324-5p, thus prohibiting access of this miRNA to one of its predicted target mRNAs, TGFBR1. Accordingly, high expression of PCAT7 in prostate carcinoma will sponge miR-324-5p and enhance TGFBR1 expression and TGF-β signaling, which can feed back to the gene and enhance its expression in cells that prepare for metastasis (88). An exactly similar scenario has been described for the small nucleolar RNA host gene 3 (SNHG3), which enhanced TGFBR1 mRNA expression by sponging away the negative regulation exerted by miR-214-3p (89). An equivalent ceRNA-mediated mechanism seems to involve regulation of TGFBR2 and involves the small nucleolar RNA host gene 16 (SNHG16) lncRNA, which is highly expressed in prostate carcinoma tissue and cells (90). High SNHG16 expression seems to sponge and inactivate miR-373-3p, which can downregulate the TGFBR2 mRNA. Thus, in prostate cancer cells with high SNHG16 expression, TGFβRII protein levels increased, causing enhanced TGF-β signaling that facilitated cancer invasiveness (90). Keeping in the same mode of action, DANCR expression correlated with Gleason score and prostate-specific antigen levels in the serum of prostate cancer patients (91). DANCR can sponge different miRNAs, among which, miR-214-5p has been linked to the negative regulation of TGF-β signaling. Both TGF-β1 ligand and TGFβRI receptor protein levels along with SMAD3 signaling can be reduced by miR-214-5p and enhanced by the antagonistic DANCR (91). This mechanism may require deeper understanding along with the fact that miR-214-3p (89), the miRNA generated by the same pre-miRNA as miR-214-5p, has been proposed to have the opposite effect on prostate cancer cell TGFBR1 levels, as described earlier. Thus, lncRNAs in prostate cancer cells can mediate regulation of the ligand and of both TGF-β receptors.

LncRNAs that can negatively regulate TGF-β signaling have also been reported in prostate cancer. Negative regulation at the SMAD protein level can be relevant in prostate cancer cells, with LINC00707 being an example of double negative feedback regulation (92). TGF-β signaling via SMAD3 and mitogen activated protein kinases (MAPKs) displaced the TF KLF6 from the LINC00707 gene, thus downregulating its expression. LINC00707 also bound to SMAD proteins and sequestered them to the cytoplasm where LINC00707 resides, thus limiting the output of TGF-β signaling in prostate cancer cell cultures (92).

Glioblastoma

The brain malignancy glioblastoma (GBM) is considered as one of the most aggressive and lethal human tumors. Of importance, several lncRNAs were described modulating molecular and cellular processes, which affected GBM heterogeneity and treatment resistance (93). For instance, TGF-β/SMAD signaling induced the expression of lncRNA-MUF (LINC00941) in GBM cells (94). Moreover, lncRNA-MUF could upregulate the effect of TGF-β inducing CAPRIN2 expression in a cis manner, apart from sponging miR-34a, which targets SNAI1. Nevertheless, although in the absence of lncRNA-MUF, the levels of SMAD2/3 phosphorylation, the mRNA levels of vimentin, connective tissue growth factor, and MYC, and the invasiveness phenotype were reduced in GBM cells. The mechanism by which this lncRNA impacted SMAD2/3 activation to promote TGF-β signaling was not clarified (94). It is also important to mention that LncRNA-MUF expression induced by TGF-β in GBM cells was correlated with temozolomide (TMZ) resistance (94). Additionally, two other lncRNAs (H19 and HOXD-AS2) that were induced by TGF-β1 through SMAD signaling were associated with TMZ resistance in GBM. The interaction of H19 and HOXD-AS2 with the K-homology splicing regulatory protein (KSPR) prevented the binding of this protein to the primary miR-198, due to a weaker association between KSRP and Drosha/Dicer complexes, leading to reduced miR-198 expression. Consequently, O6-methylguanine methyltransferase, which is a target of miR-198, was elevated, driving TMZ resistance of GBM cells because of its reverse effect on DNA alkylation by removing the methyl groups from TMZ-induced O6-methyguanine lesions (95, 96). Another lncRNA whose expression was correlated with the worst prognosis of GBM patients was the MIR4435-2HG (97). The relevance of this lncRNA to TGF-β signaling is represented by its role in culture as a ceRNA binding to miR-1224-5p, which has TGFBR2 transcripts as a target. Finally, miR-133b-3p, which possibly targets TGFB1 transcripts, bound directly to the Lnc HOXA transcript antisense RNA, myeloid-specific 1 (HOTAIRM1) in high-grade gliomas and in malignant transformed fibroblasts (98). Thus, by competing with miR-133b-3p, HOTAIRM1 increased TGFB1 expression and TGF-β signaling in gliomas. Nevertheless, how the expressions of MIR4435-2HG and HOTAIRM1 were regulated and how miR-133b-3p regulated TGFB1 mRNA in GBM cells remain open questions.

Conclusions

The large number of ncRNA genes that are widespread in the human genome suggest that the biological impact of such genes in diverse aspects of human biology will continue being uncovered actively in the near future and will also continue permeating cancer biology and TGF-β signaling. The examples presented in this article (also summarized in Table 1) are not exhaustive, yet they represent mechanisms of positive and negative signaling of the TGF-β pathway. We did not review every tumor type (e.g. hematopoetic tumors) but selected those types where the evidence for lncRNA functions linked to TGF-β signaling is stronger. Other TGF-β family pathways (activin, BMP, growth and differentiation factor (GDF), and Müllerian inhibiting substance (MIS)) are relevant to consider from a lncRNA perspective, and these are not discussed here. As explained earlier, the mechanisms may entail regulation at the ligand, receptor, SMAD, and signaling via alternative pathways, and also regulation at the chromatin-transcriptional level. The ceRNA mechanism appears dominant, yet the multifunctionality of every single miRNA generates anxiety about the specificity of the proposed mechanism and the reliability of the mechanism. This complexity always brings in mind that a single lncRNA or miRNA cannot be highly specific only for TGF-β signaling. Thus, modern studies do have to consider analyses of some of the alternative targets of these RNA molecules. Throughout our article, we attempted to provide some critical views on specific mechanistic models and even more around the lack of such mechanisms, in studies that correlate lncRNA expression to that of TGF-β pathway genes, EMT genes, and to the survival of patients. The latter is an abundant feature in lncRNA studies, facilitated by the availability of databases, and always suffers from the lack of validation of these predictions using cancer patient specimen and complementary (to transcriptomic) techniques by the investigators. Despite such criticism, the lncRNA field evolves rapidly, and the RNA-based components that complement key signaling events in TGF-β signal transduction enrich our knowledge and provide new ideas about molecular links that can generate explanations to previously unresolved problems of signal transduction in the context of human cancer.

Table 1. Regulatory network of TGF-β signaling and lncRNAs in tumors.

LncRNA	Mechanism of action	Cancer type	Ref.
Oncogenic action
LncRNA-ATB	ceRNA of several miRNAs: miR-204-3p; miR‑141‑3p; miR-200c (targeting CDK2)	Breast; Ovarian; Colorectal	(13–15, 34, 73, 74)
Smyca	Increases SMAD3/4 complex stability	Breast	(16)
TMPO-AS1	Enhances TGFBR1 and TGFBR2 mRNA expression	Breast	(20)
LETS1	Facilitates SMAD7 polyubiquitination and its degradation through NFAT5 complex and NR4A1 regulation	Breast	(22)
CASC15	ceRNA of miR-23b-3p and miR-24-3p to enhance SMAD3 expression	Ovarian	(27)
PCAT6	ceRNA of miR-143-3p to enhance TAK1/ MAP3K7 mRNA expression	Ovarian	(28, 29)
PVT1	ceRNA of miR-148a-3p to enhance AGO1 mRNA expression	Ovarian	(30)
LINC02323	ceRNA of miR-1343-3p to enhance TGFBR1 mRNA levels	Ovarian; Lung	(31, 32)
MIR210HG	ceRNA of miR-337-3p and miR-137 to enhance HMGA2 expression	Endometrial	(36)
LINC01116	Enhances SNAI1 and SNAI2 expression	Head and neck	(39)
MIR4435-2HG	Upregulates TGF-β1 expression	Head and neck	(40)
CASC18	ceRNA of miR-20a-3p, increasing TGFB2 mRNA expression	Head and neck	(41)
Lnc-PNRC2-1	Silencing decreases the expression of EMT markers	Head and neck	(44)
LINC00941 or lnc RNA-MUF	Induces CAPRIN2 expression in a cis manner and sponges miR-34a to promote SNAI1 expression	Glioblastoma	(94)
MIR4435-2HG	ceRNA of miR-1224-5p, enhancing TGFBR2 mRNA levels	Glioblastoma	(97)
HOTAIRM1	ceRNA of miR-133b-3p, increasing TGFB1 mRNA expression	Glioblastoma	(98)
Linc02470	ceRNA of miR-143-3p, increasing SMAD3 mRNA expression	Bladder	(84)
CASC9	ceRNA of miR-758-3p, increasing TGFB2 mRNA expression	Bladder	(85)
XIST	ceRNA of miR-141-3p, increasing TGFB2 mRNA expression	Pancreatic adenocarcinoma	(61)
NNT-AS1	Contributes positively to TGFB1, TGFBR1, and SMAD5 mRNA expression	Hepatocellular carcinoma	(67)
MEG8	ceRNA of miR-367-3p, increasing 14-3-3ζ expression, which suppresses TGFβR1 degradation	Hepatocellular carcinoma	(68)
TUG1	Induces TWIST1 expression	Colorectal	(76)
CTBP1-AS2	ceRNA of miR-93-5p, increasing TGFB1 mRNA expression	Colorectal	(78)
LINC00941	Binds to SMAD4 enhancing the protein stability by competing with β-TrCP	Colorectal	(79)
MIR100HG	Binds to HuR, which promotes TGFB1 mRNA stabilization, followed by secretion of pro-oncogenic TGF-β1	Lung; Prostate	(46)
LINC01232	Associates with IGFBP2 to promote TGFBR1 mRNA stability	Lung	(47)
LINC00511	ceRNA of miR-98-5p, increasing TGFBR1 mRNA levels	Lung	(48)
NORAD	Associates with importin-β1 facilitating SMAD3 nuclear translocation	Lung	(51)
LINC00273	ceRNA of miR-200a-3p, increasing ZEB1 levels	Lung	(53)
lnc-MMP2-2	ceRNA of miR-1207-5p, increasing EPB41L5 levels	Lung	(54)
PCAT7	ceRNA of miR-324-5p, increasing TGFBR1 levels	Prostate	(88)
SNHG3	ceRNA of miR-214-3p, increasing TGFBR1 levels	Prostate	(89)
SNHG16	ceRNA of miR-373-3p, increasing TGFBR2 levels	Prostate	(90)
DANCR	ceRNA of miR-214-5p, increasing TGFB1, TGFBR2, and SMAD3 levels	Prostate	(91)
Tumor suppressor
TUSC7	ceRNA of miR-1224-3p, repressing TGFBR2 levels	Breast	(18)
ADAMTS9-AS2	Interacts with RPL22 to decrease SMAD2 expression	Breast	(17)
LINC00665	Translates to the CIP2A peptide, which inhibits the PI3K/AKT/NF-κB pathway	Breast	(24)
SBF2-AS1	ceRNA of miR-302b-3p and miR-361-5p, which decrease TGFB1 mRNA levels	Head and neck; Pancreatic adenocarcinoma	(42, 70, 99)
EPB41L4A-AS2	Interacts with YBX1 reducing the stability of SNAI1 mRNA and sponges miR-107 to promote LATS2 expression	Head and neck	(45)
PLAC2	Induces miR-663 expression, which targets TGFB1 mRNA	Bladder	(82)
MIR497HG	Attenuates YAP/SMAD3 complex	Bladder	(83)
LINC00261	Network between FOXA2 and LINC00261 regulates E-cadherin expression and induces SMAD3 ubiquitin-proteasome-mediated degradation	Pancreatic adenocarcinoma; Hepatocellular carcinoma	(63, 71)
LOC646329-variant D	ceRNA of miR-29b-1, increasing SMAD3 and p21 expression	Colorectal	(77)
SMASR	Interacts directly with SMAD3 repressing SMAD signaling	Lung	(55)
LITATS1	Associates with TGFβRI and its E3 ubiquitin ligase SMURF2, inducing the degradation of TGFβRI	Lung	(56)
TGFB2-AS1	Interacts with the polycomb repressor complex 2 adaptor protein EED, blocking TGF-β signaling responses	Lung	(57)
LINC00707	Sequesters SMAD proteins to the cytoplasm	Prostate	(92)
TGF-β, transforming growth factor β; IncRNA, long non-coding RNAs.

Acknowledgments

We express our appreciation for the support of Dr. Carl-Henrik Heldin through the years of our research program. We thank past and present members of our group for their scientific contributions. Due to space limitations, not all relevant publications are discussed, and we apologize to their authors. D.M. Rodrigues-Junior: he wrote the sections on breast, ovarian, endometrial, heand and neck, pancreatic, hepatocellular, colorectal, bladder cancer and glioblastoma. A. Moustakas: he wrote the sections on abstract, introduction, TGF-β signaling, Long non-coding RNAs, lung cancer, prostate cancer and conclusions. Both authors collected the cited references, edited the draft several times and contributed to the revision of the manuscript. Both authors contributed with research funds to this work.

Notes on contributors

DMR-J and AM wrote and revised the manuscript.

ORCID

Dorival Mendes Rodrigues-Junior https://orcid.org/0000-0002-8861-9240

Aristidis Moustakas https://orcid.org/0000-0001-9131-3827

References

1.	Li P, Elowitz MB. Communication codes in developmental signaling pathways. Development. 2019;146(12):dev170977. doi: 10.1242/dev.170977
2.	Massagué J, Sheppard D. TGF-b signaling in health and disease. Cell. 2023;186(19):4007–37. doi: 10.1016/j.cell.2023.07.036
3.	Morikawa M, Koinuma D, Miyazono K, Heldin C-H. Genome-wide mechanisms of Smad binding. Oncogene. 2013;32(13):1609–15. doi: 10.1038/onc.2012.191
4.	Papoutsoglou P, Moustakas A. Long non-coding RNAs and TGF-b signaling in cancer. Cancer Sci. 2020;111(8):2672–81. doi: 10.1111/cas.14509
5.	Morikawa M, Derynck R, Miyazono K. TGF-b and the TGF-b family: context-dependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol. 2016;8(5):a021873. doi: 10.1101/cshperspect.a021873
6.	Tsubakihara Y, Moustakas A. Epithelial-mesenchymal transition and metastasis under the control of transforming growth factor b. Int J Mol Sci. 2018;19(11):3672. doi: 10.3390/ijms19113672
7.	Bellomo C, Caja L, Moustakas A. Transforming growth factor b as regulator of cancer stemness and metastasis. Br J Cancer. 2016;115(7):761–9. doi: 10.1038/bjc.2016.255
8.	Mattick JS, Amaral PP, Carninci P, Carpenter S, Chang HY, Chen LL, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023;24(6):430–47. doi: 10.1038/s41580-022-00566-8
9.	Frankish A, Diekhans M, Jungreis I, Lagarde J, Loveland JE, Mudge JM, et al. Gencode 2021. Nucleic Acids Res. 2021;49(D1):D916–23. doi: 10.1093/nar/gkaa1087
10.	Huang JZ, Chen M, Chen D, Gao XC, Zhu S, Huang H, et al. A peptide encoded by a putative lncRNA HOXB-AS3 suppresses colon cancer growth. Mol Cell. 2017;68(1):171–84.e6. doi: 10.1016/j.molcel.2017.09.015
11.	Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi: 10.3322/caac.21708
12.	Sideris N, Dama P, Bayraktar S, Stiff T, Castellano L. LncRNAs in breast cancer: a link to future approaches. Cancer Gene Ther. 2022;29(12):1866–77. doi: 10.1038/s41417-022-00487-w
13.	Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, et al. A long noncoding RNA activated by TGF-b promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell. 2014;25(5):666–81. doi: 10.1016/j.ccr.2014.03.010
14.	Xiao H, Zhang F, Zou Y, Li J, Liu Y, Huang W. The function and mechanism of long non-coding RNA-ATB in cancers. Front Physiol. 2018;9:321. doi: 10.3389/fphys.2018.00321
15.	El-Ashmawy NE, Hussien FZ, El-Feky OA, Hamouda SM, Al-Ashmawy GM. Serum LncRNA-ATB and FAM83H-AS1 as diagnostic/prognostic non-invasive biomarkers for breast cancer. Life Sci. 2020;259:118193. doi: 10.1016/j.lfs.2020.118193
16.	Chen HY, Chan SJ, Liu X, Wei AC, Jian RI, Huang KW, et al. Long noncoding RNA Smyca coactivates TGF-b/Smad and Myc pathways to drive tumor progression. J Hematol Oncol. 2022;15(1):85. doi: 10.1186/s13045-022-01306-3
17.	Ni K, Huang Z, Zhu Y, Xue D, Jin Q, Zhang C, et al. The lncRNA ADAMTS9-AS2 regulates RPL22 to modulate TNBC progression via controlling the TGF-b signaling pathway. Front Oncol. 2021;11:654472. doi: 10.3389/fonc.2021.654472
18.	Zheng BH, He ZX, Zhang J, Ma JJ, Zhang HW, Zhu W, et al. The biological function of TUSC7/miR-1224-3p axis in triple-negative breast cancer. Cancer Manag Res. 2021;13:5763–74. doi: 10.2147/CMAR.S305865
19.	Zhang Y, O’Leary MN, Peri S, Wang M, Zha J, Melov S, et al. Ribosomal proteins Rpl22 and Rpl22l1 control morphogenesis by regulating pre-mRNA splicing. Cell Rep. 2017;18(2):545–56. doi: 10.1016/j.celrep.2016.12.034
20.	Mitobe Y, Ikeda K, Sato W, Kodama Y, Naito M, Gotoh N, et al. Proliferation-associated long noncoding RNA, TMPO-AS1, is a potential therapeutic target for triple-negative breast cancer. Cancer Sci. 2020;111(7):2440–50. doi: 10.1111/cas.14498
21.	Wo L, Zhang B, You X, Hu Y, Gu Z, Zhang M, et al. Up-regulation of LncRNA UCA1 by TGF-b promotes doxorubicin resistance in breast cancer cells. Immunopharmacol Immunotoxicol. 2022;44(4):492–9. doi: 10.1080/08923973.2022.2054428
22.	Fan C, Gonzalez-Prieto R, Kuipers TB, Vertegaal ACO, van Veelen PA, Mei H, et al. The lncRNA LETS1 promotes TGF-b-induced EMT and cancer cell migration by transcriptionally activating a TbR1-stabilizing mechanism. Sci Signal. 2023;16(790):eadf1947. doi: 10.1126/scisignal.adf1947
23.	Zhou F, Drabsch Y, Dekker TJ, de Vinuesa AG, Li Y, Hawinkels LJ, et al. Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF-b signalling. Nat Commun. 2014;5:3388. doi: 10.1038/ncomms4388
24.	Guo B, Wu S, Zhu X, Zhang L, Deng J, Li F, et al. Micropeptide CIP2A-BP encoded by LINC00665 inhibits triple-negative breast cancer progression. EMBO J. 2020;39(1):e102190. doi: 10.15252/embj.2019102190
25.	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492
26.	Chen M, Lei N, Tian W, Li Y, Chang L. Recent advances of non-coding RNAs in ovarian cancer prognosis and therapeutics. Ther Adv Med Oncol. 2022;14:17588359221118010. doi: 10.1177/17588359221118010
27.	Lin H, Xu X, Chen K, Fu Z, Wang S, Chen Y, et al. LncRNA CASC15, MiR-23b cluster and SMAD3 form a novel positive feedback loop to promote epithelial-mesenchymal transition and metastasis in ovarian cancer. Int J Biol Sci. 2022;18(5):1989–2002. doi: 10.7150/ijbs.67486
28.	Tan X, Shao Y, Teng Y, Liu S, Li W, Xue L, et al. The cancer-testis long non-coding RNA PCAT6 facilitates the malignant phenotype of ovarian cancer by sponging miR-143-3p. Front Cell Dev Biol. 2021;9:593677. doi: 10.3389/fcell.2021.593677
29.	Huang FT, Peng JF, Cheng WJ, Zhuang YY, Wang LY, Li CQ, et al. MiR-143 Targeting TAK1 attenuates pancreatic ductal adenocarcinoma progression via MAPK and NF-kB pathway in vitro. Dig Dis Sci 2017; 62(4): 944–57. doi: 10.1007/s10620-017-4472-7
30.	Wu Y, Gu W, Han X, Jin Z. LncRNA PVT1 promotes the progression of ovarian cancer by activating TGF-b pathway via miR-148a-3p/AGO1 axis. J Cell Mol Med. 2021;25(17):8229–43. doi: 10.1111/jcmm.16700
31.	Li Y, Zhao Z, Sun D, Li Y. Novel long noncoding RNA LINC02323 promotes cell growth and migration of ovarian cancer via TGF-b receptor 1 by miR-1343-3p. J Clin Lab Anal. 2021;35(2):e23651. doi: 10.1002/jcla.23651
32.	Zhang X, Du L, Han J, Li X, Wang H, Zheng G, et al. Novel long non-coding RNA LINC02323 promotes epithelial-mesenchymal transition and metastasis via sponging miR-1343-3p in lung adenocarcinoma. Thorac Cancer. 2020;11(9):2506–16. doi: 10.1111/1759-7714.13562
33.	Rodrigues-Junior DM, Tsirigoti C, Lim SK, Heldin C-H, Moustakas A. Extracellular vesicles and transforming growth factor b signaling in cancer. Front Cell Dev Biol. 2022;10:849938. doi: 10.3389/fcell.2022.849938
34.	Yuan D, Guo T, Zhu D, Ge H, Zhao Y, Huang A, et al. Exosomal lncRNA ATB derived from ovarian cancer cells promotes angiogenesis via regulating miR-204-3p/TGFbR2 axis. Cancer Manag Res. 2022;14:327–37. doi: 10.2147/CMAR.S330368
35.	Shetty A, Venkatesh T, Kabbekodu SP, Tsutsumi R, Suresh PS. LncRNA-miRNA-mRNA regulatory axes in endometrial cancer: a comprehensive overview. Arch Gynecol Obstet. 2022;306(5):1431–47. doi: 10.1007/s00404-022-06423-5
36.	Ma J, Kong FF, Yang D, Yang H, Wang C, Cong R, et al. lncRNA MIR210HG promotes the progression of endometrial cancer by sponging miR-337-3p/137 via the HMGA2-TGF-b/Wnt pathway. Mol Ther Nucleic Acids. 2021;24:905–22. doi: 10.1016/j.omtn.2021.04.011
37.	Iyer NG, Tan DS, Tan VK, Wang W, Hwang J, Tan NC, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer. 2015;121(10):1599–607. doi: 10.1002/cncr.29251
38.	Wang Y, Wang S, Ren Y, Zhou X. The role of lncRNA crosstalk in leading cancer metastasis of head and neck squamous cell carcinoma. Front Oncol. 2020;10:561833. doi: 10.3389/fonc.2020.561833
39.	Wu J, Chen Z, Zhang L, Cao J, Li X, Gong Z, et al. Knockdown of LINC01116 inhibits cell migration and invasion in head and neck squamous cell carcinoma through epithelial-mesenchymal transition pathway. J Cell Biochem. 2020;121(1):867–75. doi: 10.1002/jcb.29331
40.	Shen H, Sun B, Yang Y, Cai X, Bi L, Deng L, et al. MIR4435-2HG regulates cancer cell behaviors in oral squamous cell carcinoma cell growth by upregulating TGF-b1. Odontology. 2020;108(4):553–9. doi: 10.1007/s10266-020-00488-x
41.	Zhou B, Zhou Y, Liu Y, Zhang H, Mao H, Peng M, et al. Association of CASC18/miR-20a-3p/TGFB2 ceRNA axis with occult lymph node metastasis in tongue squamous cell carcinoma. Mol Med. 2021;27(1):85. doi: 10.1186/s10020-021-00345-9
42.	Li Y, Tang B, Lyu K, Yue H, Wei F, Xu Y, et al. Low expression of lncRNA SBF2-AS1 regulates the miR-302b-3p/TGFBR2 axis, promoting metastasis in laryngeal cancer. Mol Carcinog. 2022;61(1):45–58. doi: 10.1002/mc.23358
43.	Pang X, Tang YL, Liang XH. Transforming growth factor-b signaling in head and neck squamous cell carcinoma: insights into cellular responses. Oncol Lett. 2018;16(4):4799–806. doi: 10.3892/ol.2018.9319
44.	Yang J, Feng E, Ren Y, Qiu S, Zhao L, Li X. Long non-coding (lnc)RNA profiling and the role of a key regulator lnc-PNRC2-1 in the transforming growth factor-b1-induced epithelial-mesenchymal transition of CNE1 nasopharyngeal carcinoma cells. J Int Med Res. 2021;49(3):300060521996515. doi: 10.1177/0300060521996515
45.	Du M, Hu X, Jiang X, Yin L, Chen J, Wen J, et al. LncRNA EPB41L4A-AS2 represses nasopharyngeal carcinoma metastasis by binding to YBX1 in the nucleus and sponging MiR-107 in the cytoplasm. Int J Biol Sci. 2021;17(8):1963–78. doi: 10.7150/ijbs.55557
46.	Papoutsoglou P, Rodrigues-Junior DM, Morén A, Bergman A, Pontén F, Coulouarn C, et al. The noncoding MIR100HG RNA enhances the autocrine function of transforming growth factor b signaling. Oncogene. 2021;40(21):3748–65. doi: 10.1038/s41388-021-01803-8
47.	Zhu L, Liu Y, Tang H, Wang P. FOXP3 activated-LINC01232 accelerates the stemness of non-small cell lung carcinoma by activating TGF-b signaling pathway and recruiting IGF2BP2 to stabilize TGFBR1. Exp Cell Res. 2022;413(2):113024. doi: 10.1016/j.yexcr.2022.113024
48.	Li C, Li Z, Yi H, Liu Z. IncRNA Linc00511 upregulation elevates TGFBR1 and participates in the postoperative distant recurrence of non-small-cell lung cancer by targeting miR-98-5p. Crit Rev Eukaryot Gene Expr. 2022;32(5):1–10. doi: 10.1615/CritRevEukaryotGeneExpr.2022039498
49.	Shi J, Li J, Yang S, Hu X, Chen J, Feng J, et al. LncRNA SNHG3 is activated by E2F1 and promotes proliferation and migration of non-small-cell lung cancer cells through activating TGF-b pathway and IL-6/JAK2/STAT3 pathway. J Cell Physiol. 2020;235(3):2891–900. doi: 10.1002/jcp.29194
50.	Yang M, He X, Huang X, Wang J, He Y, Wei L. LncRNA MIR4435-2HG-mediated upregulation of TGF-b1 promotes migration and proliferation of nonsmall cell lung cancer cells. Environ Toxicol. 2020;35(5):582–90. doi: 10.1002/tox.22893
51.	Kawasaki N, Miwa T, Hokari S, Sakurai T, Ohmori K, Miyauchi K, et al. Long noncoding RNA NORAD regulates transforming growth factor-b signaling and epithelial-to-mesenchymal transition-like phenotype. Cancer Sci. 2018;109(7):2211–20. doi: 10.1111/cas.13626
52.	Yao J, Lu X, Wang Y, Li J, Ni B. Long noncoding RNAs AC026904.1 is essential for TGF-b-induced migration and epithelial-mesenchymal transition through functioning as an enhancer of slug in lung cancer cells. Environ Toxicol. 2020;35(9):942–51. doi: 10.1002/tox.22930
53.	Sarkar A, Rahaman A, Biswas I, Mukherjee G, Chatterjee S, Bhattacharjee S, et al. TGFb mediated LINC00273 upregulation sponges mir200a-3p and promotes invasion and metastasis by activating ZEB1. J Cell Physiol. 2020;235(10):7159–72. doi: 10.1002/jcp.29614
54.	Wu D, Deng S, Li L, Liu T, Zhang T, Li J, et al. TGF-b1-mediated exosomal lnc-MMP2-2 increases blood-brain barrier permeability via the miRNA-1207-5p/EPB41L5 axis to promote non-small cell lung cancer brain metastasis. Cell Death Dis. 2021;12(8):721. doi: 10.1038/s41419-021-04004-z
55.	Xu L, Liu W, Li T, Hu Y, Wang Y, Huang L, et al. Long non-coding RNA SMASR inhibits the EMT by negatively regulating TGF-b/Smad signaling pathway in lung cancer. Oncogene. 2021;40(20):3578–92. doi: 10.1038/s41388-021-01760-2
56.	Fan C, Wang Q, Kuipers TB, Cats D, Iyengar PV, Hagenaars SC, et al. LncRNA LITATS1 suppresses TGF-b-induced EMT and cancer cell plasticity by potentiating TbRI degradation. EMBO J. 2023;42(10):e112806. doi: 10.15252/embj.2022112806
57.	Papoutsoglou P, Tsubakihara Y, Caja L, Morén A, Pallis P, Ameur A, et al. The TGFB2-AS1 lncRNA regulates TGF-b signaling by modulating corepressor activity. Cell Rep. 2019;28(12):3182–98.e11. doi: 10.1016/j.celrep.2019.08.028
58.	Zhou C, Wang D, Li J, Wang Q, Wo L, Zhang X, et al. TGFB2-AS1 inhibits triple-negative breast cancer progression via interaction with SMARCA4 and regulating its targets TGFB2 and SOX2. Proc Natl Acad Sci U S A. 2022;119(39):e2117988119. doi: 10.1073/pnas.2117988119
59.	Gong R, Jiang Y. Non-coding RNAs in pancreatic ductal adenocarcinoma. Front Oncol. 2020;10:309. doi: 10.3389/fonc.2020.00309
60.	Ko CC, Hsieh YY, Yang PM. Long on-coding RNA MIR31HG promotes the transforming growth factor b-induced epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma cells. Int J Mol Sci. 2022;23(12):6559. doi: 10.3390/ijms23126559
61.	Sun J, Zhang Y. LncRNA XIST enhanced TGF-b2 expression by targeting miR-141-3p to promote pancreatic cancer cells invasion. Biosci Rep. 2019;39(7):BSR20190332. doi: 10.1042/BSR20190332
62.	Takahashi K, Ota Y, Kogure T, Suzuki Y, Iwamoto H, Yamakita K, et al. Circulating extracellular vesicle-encapsulated HULC is a potential biomarker for human pancreatic cancer. Cancer Sci. 2020;111(1):98–111. doi: 10.1111/cas.14232
63.	Dorn A, Glass M, Neu CT, Heydel B, Huttelmaier S, Gutschner T, et al. LINC00261 is differentially expressed in pancreatic cancer subtypes and regulates a pro-epithelial cell identity. Cancers (Basel). 2020;12(5):1227. doi: 10.3390/cancers12051227
64.	Tang Y, Shu G, Yuan X, Jing N, Song J. FOXA2 functions as a suppressor of tumor metastasis by inhibition of epithelial-to-mesenchymal transition in human lung cancers. Cell Res. 2011;21(2):316–26. doi: 10.1038/cr.2010.126
65.	Huang Z, Zhou JK, Peng Y, He W, Huang C. The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer. 2020;19(1):77. doi: 10.1186/s12943-020-01188-4
66.	Han M, Liao Z, Liu F, Chen X, Zhang B. Modulation of the TGF-b signaling pathway by long noncoding RNA in hepatocellular carcinoma. Biomark Res. 2020;8(1):70. doi: 10.1186/s40364-020-00252-x
67.	Wang Y, Yang L, Dong X, Yang X, Zhang X, Liu Z, et al. Overexpression of NNT-AS1 activates TGF-b signaling to decrease tumor CD4 lymphocyte infiltration in hepatocellular carcinoma. Biomed Res Int. 2020;2020:8216541. doi: 10.1155/2020/8216541
68.	Lou J, Yan W, Li QY, Zhu AK, Tan BQ, Dong R, et al. LncRNA MEG8 plays an oncogenic role in hepatocellular carcinoma progression through miR-367-3p/14-3-3z/TGFbR1 axis. Neoplasma. 2021;68(2):273–82. doi: 10.4149/neo_2020_200730N785
69.	Lu J, Guo H, Treekitkarnmongkol W, Li P, Zhang J, Shi B, et al. 14-3-3z Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell. 2009;16(3):195–207. doi: 10.1016/j.ccr.2009.08.010
70.	Wu YH, Yu B, Chen WX, Ai X, Zhang W, Dong W, et al. Downregulation of lncRNA SBF2-AS1 inhibits hepatocellular carcinoma proliferation and migration by regulating the miR-361-5p/TGF-b1 signaling pathway. Aging (Albany NY). 2021;13(15):19260–71. doi: 10.18632/aging.203248
71.	Chen Z, Xiang L, Li L, Ou H, Fang Y, Xu Y, et al. TGF-b1 induced deficiency of linc00261 promotes epithelial-mesenchymal-transition and stemness of hepatocellular carcinoma via modulating SMAD3. J Transl Med. 2022;20(1):75. doi: 10.1186/s12967-022-03276-z
72.	Ghafouri-Fard S, Hussen BM, Gharebaghi A, Eghtedarian R, Taheri M. LncRNA signature in colorectal cancer. Pathol Res Pract. 2021;222:153432. doi: 10.1016/j.prp.2021.153432
73.	Gao Z, Zhou H, Wang Y, Chen J, Ou Y. Regulatory effects of lncRNA ATB targeting miR-200c on proliferation and apoptosis of colorectal cancer cells. J Cell Biochem. 2020;121(1):332–43. doi: 10.1002/jcb.29180
74.	Liu X, Wang C. Long non-coding RNA ATB is associated with metastases and promotes cell invasion in colorectal cancer via sponging miR-141-3p. Exp Ther Med. 2020;20(6):261. doi: 10.3892/etm.2020.9391
75.	Yang X, Tao H, Wang C, Chen W, Hua F, Qian H. lncRNA-ATB promotes stemness maintenance in colorectal cancer by regulating transcriptional activity of the b-catenin pathway. Exp Ther Med. 2020;19(4):3097–103. doi: 10.3892/etm.2020.8558
76.	Shen X, Hu X, Mao J, Wu Y, Liu H, Shen J, et al. The long noncoding RNA TUG1 is required for TGF-b/TWIST1/EMT-mediated metastasis in colorectal cancer cells. Cell Death Dis. 2020;11(1):65. doi: 10.1038/s41419-020-2254-1
77.	Javanmard AR, Dokanehiifard S, Bohlooli M, Soltani BM. LOC646329 long non-coding RNA sponges miR-29b-1 and regulates TGFb signaling in colorectal cancer. J Cancer Res Clin Oncol. 2020;146(5):1205–15. doi: 10.1007/s00432-020-03145-6
78.	Li Q, Yue W, Li M, Jiang Z, Hou Z, Liu W, et al. Downregulating long non-coding RNAs CTBP1-AS2 inhibits colorectal cancer development by modulating the miR-93-5p/TGF-b/SMAD2/3 pathway. Front Oncol. 2021;11:626620. doi: 10.3389/fonc.2021.626620
79.	Wu N, Jiang M, Liu H, Chu Y, Wang D, Cao J, et al. LINC00941 promotes CRC metastasis through preventing SMAD4 protein degradation and activating the TGF-b/SMAD2/3 signaling pathway. Cell Death Differ. 2021;28(1):219–32. doi: 10.1038/s41418-020-0596-y
80.	Huang Y, Luo Y, Ou W, Wang Y, Dong D, Peng X, et al. Exosomal lncRNA SNHG10 derived from colorectal cancer cells suppresses natural killer cell cytotoxicity by upregulating INHBC. Cancer Cell Int. 2021;21(1):528. doi: 10.1186/s12935-021-02221-2
81.	Li Y, Li G, Guo X, Yao H, Wang G, Li C. Non-coding RNA in bladder cancer. Cancer Lett. 2020;485:38–44. doi: 10.1016/j.canlet.2020.04.023
82.	Zhang Z, Ao P, Han H, Zhang Q, Chen Y, Han J, et al. LncRNA PLAC2 upregulates miR-663 to downregulate TGF-b1 and suppress bladder cancer cell migration and invasion. BMC Urol. 2020;20(1):94. doi: 10.1186/s12894-020-00663-w
83.	Zhuang C, Liu Y, Fu S, Yuan C, Luo J, Huang X, et al. Silencing of lncRNA MIR497HG via CRISPR/Cas13d induces bladder cancer progression through promoting the crosstalk between Hippo/Yap and TGF-b/Smad signaling. Front Mol Biosci. 2020;7:616768. doi: 10.3389/fmolb.2020.616768
84.	Huang CS, Tsai CH, Yu CP, Wu YS, Yee MF, Ho JY, et al. Long noncoding RNA LINC02470 sponges MicroRNA-143-3p and enhances SMAD3-mediated epithelial-to-mesenchymal transition to promote the aggressive properties of bladder cancer. Cancers (Basel). 2022;14(4):968. doi: 10.3390/cancers14040968
85.	Zhang Z, Chen F, Zhan H, Chen L, Deng Q, Xiong T, et al. lncRNA CASC9 sponges miR7583p to promote proliferation and EMT in bladder cancer by upregulating TGFb2. Oncol Rep. 2021;45(1):265–77. doi: 10.3892/or.2020.7852
86.	Shi H, Xie J, Wang K, Li W, Yin L, Wang G, et al. LINC01451 drives epithelial-mesenchymal transition and progression in bladder cancer cells via LIN28/TGF-b/Smad pathway. Cell Signal. 2021;81:109932. doi: 10.1016/j.cellsig.2021.109932
87.	Guan Z, Song Y, Ma J, Li F, Zhao X, Liang G, et al. Altered expression of lncRNA NCK1-AS1 distinguished patients with prostate cancer from those with benign prostatic hyperplasia. Oncol Lett. 2019;18(6):6379–84. doi: 10.3892/ol.2019.11039
88.	Lang C, Dai Y, Wu Z, Yang Q, He S, Zhang X, et al. SMAD3/SP1 complex-mediated constitutive active loop between lncRNA PCAT7 and TGF-b signaling promotes prostate cancer bone metastasis. Mol Oncol. 2020;14(4):808–28. doi: 10.1002/1878-0261.12634
89.	Xi X, Hu Z, Wu Q, Hu K, Cao Z, Zhou J, et al. High expression of small nucleolar RNA host gene 3 predicts poor prognosis and promotes bone metastasis in prostate cancer by activating transforming growth factor-b signaling. Bioengineered. 2022;13(1):1895–907. doi: 10.1080/21655979.2021.2020393
90.	Weng W, Liu C, Li G, Ruan Q, Li H, Lin N, et al. Long non-coding RNA SNHG16 functions as a tumor activator by sponging miR3733p to regulate the TGFbR2/SMAD pathway in prostate cancer. Mol Med Rep. 2021;24(6):843. doi: 10.3892/mmr.2021.12483
91.	Deng H, Zhu B, Dong Z, Jiang H, Zhao X, Wu S. miR-214-5p targeted by LncRNA DANCR mediates TGF-b signaling pathway to accelerate proliferation, migration and inhibit apoptosis of prostate cancer cells. Am J Transl Res. 2021;13(4):2224–40.
92.	Gélabert C, Papoutsoglou P, Golàn I, Ahlström E, Ameur A, Heldin C-H, et al. The long non-coding RNA LINC00707 interacts with Smad proteins to regulate TGFb signaling and cancer cell invasion. Cell Commun Signal. 2023;21(1):271. doi: 10.1186/s12964-023-01273-3
93.	DeSouza PA, Qu X, Chen H, Patel B, Maher CA, Kim AH. Long, noncoding RNA dysregulation in glioblastoma. Cancers (Basel). 2021;13(7):1604. doi: 10.3390/cancers13071604
94.	Shree B, Tripathi S, Sharma V. Transforming growth factor-B-regulated LncRNA-MUF promotes invasion by modulating the miR-34a snail1 axis in glioblastoma multiforme. Front Oncol. 2021;11:788755. doi: 10.3389/fonc.2021.788755
95.	Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26(25):4189–99. doi: 10.1200/JCO.2007.11.5964
96.	Nie E, Jin X, Miao F, Yu T, Zhi T, Shi Z, et al. TGF-b1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT. Neuro Oncol. 2021;23(3):435–46. doi: 10.1093/neuonc/noaa198
97.	Xu H, Zhang B, Yang Y, Li Z, Zhao P, Wu W, et al. LncRNA MIR4435-2HG potentiates the proliferation and invasion of glioblastoma cells via modulating miR-1224-5p/TGFBR2 axis. J Cell Mol Med. 2020;24(11):6362–72. doi: 10.1111/jcmm.15280
98.	Wang H, Li H, Jiang Q, Dong X, Li S, Cheng S, et al. HOTAIRM1 Promotes Malignant progression of transformed fibroblasts in glioma stem-like cells remodeled microenvironment via regulating miR-133b-3p/TGFb axis. Front Oncol. 2021;11:603128. doi: 10.3389/fonc.2021.603128
99.	Li Y, Liu G, Li X, Dong H, Xiao W, Lu S. Long non-coding RNA SBF2-AS1 promotes hepatocellular carcinoma progression through regulation of miR-140-5p-TGFBR1 pathway. Biochem Biophys Res Commun. 2018;503(4):2826–32. doi: 10.1016/j.bbrc.2018.08.047